Ipamorelin

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide developed in the late 1990s as a selective growth-hormone-releasing peptide (GHRP). It contains non-natural residues (Aib, D-2-Nal, D-Phe) that confer protease resistance. Among the GHRPs, Ipamorelin is one of the most selective for growth hormone release with minimal effects on prolactin, ACTH, or cortisol in published preclinical and early clinical studies.

Mechanism of action (preclinical evidence)

Ipamorelin is an agonist of the growth hormone secretagogue receptor type 1a (GHSR1a), the same receptor as endogenous ghrelin. Activation triggers Gαq-coupled signaling in pituitary somatotroph cells, leading to growth hormone release. Unlike non-selective GHRPs, Ipamorelin shows minimal cross-activation of other anterior pituitary axes in research settings.

Research applications

• GHSR1a receptor binding and pharmacology
• Pituitary somatotroph cell function studies
• Ghrelin pathway investigations
• Growth hormone release dynamics in rodent models
• Comparative studies with other GHRPs (GHRP-2, GHRP-6, hexarelin)

Storage and handling

Store lyophilised Ipamorelin at -20 °C, sealed and protected from light. Reconstitute in sterile water for short-term assays; aliquot for freezer storage when not in immediate use.

Regulatory status

Ipamorelin is not approved by FDA, EMA, or any other regulator for human or veterinary use. WADA prohibits all GHRPs (S2 category). Supplied strictly for laboratory research only.